R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
R&D Sponsored 12 Questions with Lucy Walker Lucy Walker is the Head of Medical Operations at the growing medical consultancy LUCENT Biopharma. Find out more in a new 12 Questions With.
R&D LSX2026: Non-opioid pain relief and pharma positivity, with ... Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.
R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
R&D Changing Faces: Pharma and biotech, March 2026 A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.
R&D Sponsored A data-driven guide to small molecule drug discovery and dev... A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
